Tempus AI, Inc. Class A (TEM)

Tempus AI's stock price has experienced volatility in the past six months. As of February 4, 2026, the share price was $53.55, representing a decline of 22.59% from February 5, 2025, when it was $69.18. The stock hit a 52-week high of $104.32 on October 8, 2025, and a 52-week low of $36.22. Key events impacting the stock include August 2025 and November 2025 earnings reports, the acquisition of Paige, the launch of Paige Predict, a strategic collaboration with NYU Langone Health, FDA 510(k) clearance, and insider selling.

The provided information does not contain specific details regarding the demand seasonality for Tempus AI, Inc.'s products and services. However, demand might be influenced by healthcare spending cycles, research and development budgets of pharmaceutical and biotechnology companies, and the prevalence and research focus on specific diseases. The increasing demand for personalized medicine and improved healthcare outcomes is a crucial driver for the healthcare AI market.

Tempus AI, Inc. is a healthcare technology company applying AI and machine learning to advance precision medicine and create "Intelligent Diagnostics". It operates in Health Information Services, providing next-generation sequencing diagnostics, PCR profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. Major products and services include Insights, Trials, Next, Algos, Hub, and Lens. Tempus AI has expanded beyond oncology to address other diseases, including psychiatric disorders and cardiology, acquiring Paige, Mpirik, and Ambry Genetics to enhance its capabilities.

Tempus AI, Inc. is headquartered in Chicago, Illinois, United States, and has extended its presence internationally. Within the United States, approximately 65% of academic medical centers and over 50% of oncologists are connected to Tempus. Furthermore, 95% of the top pharmaceutical companies (based on 2024 revenue data) partner with Tempus.

Tempus AI's brand reputation was impacted in May 2025 by a report from Spruce Point Capital, estimating a potential downside for TEM stock and raising concerns regarding Tempus's AI. Tempus AI responded to these accusations. The company's stock had risen 35% for the year by May 2025, with strong year-to-date gains of almost 60% since the beginning of 2025, and the stock subsequently recovered from the short report's impact. Tempus AI generally scores well in market analysis, with a MarketRank™ score higher than 72% of companies evaluated by MarketBeat. The company has received a consensus rating of "Hold" from analysts, with an average price target of $87.20.

Tempus AI, Inc. has a significant institutional ownership base, with 596 institutional owners and shareholders holding a total of 113,422,178 shares. Major institutional owners include Vanguard Group Inc., Baillie Gifford & Co., ARK Investment Management LLC, BlackRock, Inc., Softbank Group Corp, JPMorgan Chase & Co., Susquehanna International Group, Llp, Catalytic Wealth RIA, LLC, ARKK - ARK Innovation ETF and Amova Asset Management Co., Ltd.